Anzeige
Mehr »
Mittwoch, 17.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
276 Leser
Artikel bewerten:
(1)

ColdZyme Launches With New Flavor and New Product Claims

STOCKHOLM, Aug. 26, 2019 /PRNewswire/ -- Enzymatica is now launching strawberry as its new flavor for ColdZyme cold spray and also introducing two new product claims - soothe sore throat and alleviate common cold symptoms. Strawberry flavored ColdZyme will be available in the majority of pharmacy chains in Sweden beginning in late August and it will be on the shelves of the remaining pharmacies from early October.

Many have requested a new flavor that appeals to both young and old, and now it is here! Enzymatica is expanding the ColdZyme family with ColdZyme Strawberry 20 ml. Studies and market surveys have shown that 20-25% of respondents prefer a flavor other than our current menthol flavor. The new flavor will be launched in Sweden and Denmark at the end of August, with product roll-out planned in other markets where ColdZyme is sold over the next few years.

ColdZyme has also received extended product claims stating that in addition to preventing and reducing the duration of colds, ColdZyme can also soothe sore throats and alleviate common cold symptoms.

"The new product claims are based on the successful results of our 2018 prospective, single-blind, randomized multicenter study in Germany. These results strengthen the documentation for ColdZyme as a safe and effective treatment for colds," says Fredrik Lindberg, CEO of Enzymatica.

The German multicenter study was carried out at six centers in Germany during the 2018 cold season. The study included 400 participants who were randomly asked either to initiate treatment with ColdZyme at the first cold symptoms, or not to start any treatment. A total of 267 people with confirmed colds were evaluated in the study. The results from the study strengthen ColdZyme's intended use of reducing the duration of colds, while also broadening its clinical benefit by showing that ColdZyme significantly reduces cold symptoms, soothe sore throats, improves quality of life and reduces the need for concurrent use of symptom-relieving medication for colds.

For more information please contact:
Fredrik Lindberg
CEO Enzymatica AB
Tel: +46 (0)708-86-53-70
Email: fredrik.lindberg@enzymatica.com

Carl-Johan Wachtmeister
Head of Corporate Communications
Enzymatica AB
Tel: +46 (0)701-88-50-21
Email: carl-johan.wachtmeister@enzymatica.com

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The company's first product is ColdZyme, which can prevent colds and reduce the duration of disease. The product has been launched in about ten markets. The strategy is to continue to grow by strengthening the Company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North. For more information, visit: www.enzymatica.com.

Enzymatica's Certified Adviser is Erik Penser Bank.

Tel: +46 (0)8-463-83-00
Email: certifiedadviser@penser.se
Enzymatica AB Ideon Science Park 223 70 Lund
Phone: +46-46-286-31-00

www.enzymatica.se
www.coldzyme.se

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/enzymatica-ab/r/coldzyme-launches-with-new-flavor-and-new-product-claims,c2888196

The following files are available for download:

https://news.cision.com/enzymatica-ab/i/coldzyme-20-strawberry,c2670698

ColdZyme 20-strawberry

© 2019 PR Newswire
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.